Opendata, web and dolomites

Tomo-FPS

Tomosynthesis is a low-dose alternate to has CT already transformed Breast Imaging, our vision is to reduce the costs, further enhance sensitivity and reduce dose, and transform portability.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Tomo-FPS project word cloud

Explore the words cloud of the Tomo-FPS project. It provides you a very rough idea of what is the project "Tomo-FPS" about.

continues    footprint    dimensions    move    reduce    disease    source    levels    fps    planar    breast    ct    consistency    magnetic    emission    radiology    imaging    device    constitutes    tomosynthesis    resolution    tomography    despite    cancer    performing    closer    limited    capability    tissues    objectivity    bone    localise    mri    objects    vary    ray    true    acquisition    60    reducing    power    market    cheaper    form    quantify    lung    small    global    2d    workhorse    panel    resonance    5bn    screening    moving    unlike    radically    transform    size    review    transformed    parts    biomarkers    nodules    speed    medical    demonstrated    changing    basic    near    computed    worldwide    subject    circa    innovation    image    ultrasound    healthcare    adaptix    visualize    flat    giving    dose    symptomatic    world    equal    modalities    safer    weight    radiation    50    90    accepted    offerings    potentially    versus    3d    dimension    progression    angle    majority    diagnostic   

Project "Tomo-FPS" data sheet

The following table provides information about the project.

Coordinator
ADAPTIX LTD 

Organization address
address: BEGBROKE SCIENCE PARK - WOODSTOCK ROAD
city: OXFORD
postcode: OX5 1PF
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.adaptiximaging.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-10-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ADAPTIX LTD UK (OXFORD) coordinator 50˙000.00

Map

 Project objective

The power of 3D X-ray imaging in healthcare in the form of Computed Tomography (CT) is widely accepted, but despite the widespread availability of CT and Magnetic Resonance Imaging (MRI) it is still the basic 2D planar X-ray that constitutes the majority (circa 60%) of medical imaging studies worldwide. Planar X-ray continues to be the “workhorse of radiology” because of its availability, low cost and small system footprint (compared to MRI and CT); its speed of image acquisition and review (compared to all other modalities); its ability to visualize tissues like bone (unlike MRI and Ultrasound); its low radiation dose (unlike CT); and its consistency and objectivity of image acquisition (unlike Ultrasound).

Tomosynthesis, a method for performing high-resolution limited-angle tomography at low dose levels, has already transformed breast cancer screening and has demonstrated an ability to near-equal CT in identifying lung nodules symptomatic of lung cancer.

Our innovation is a Flat Panel X-ray Source (FPS) that allows tomosynthesis without any moving parts. This will reduce costs and enhance acquisition speed and allows the source to be closer to the subject, reducing power needs and further reducing cost.

Unlike current tomosynthesis devices that move the source in 1 dimension, a system using an FPS could vary emission in 2 dimensions which could enhance depth resolution and the ability to localise objects. This would enhance the ability to quantify features, including biomarkers of disease progression.

Adaptix will transform planar X-ray by giving it true 3D capability, making it safer by reducing dose (versus CT, and potentially versus planar X-ray), making the systems 50% cheaper than existing market offerings and reducing weight and size by 90%. By doing this we will be improving access to the world’s most important medical diagnostic device and radically changing a $5bn global market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TOMO-FPS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TOMO-FPS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More